전립선암 예방과 치료 : 다양한 기술과 세계 시장

Highlights:

The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.

The global market for prostate cancer pharmaceuticals is expected to grow from $17.5 billion in 2023 to $29.6 billion by the end of 2028, at a CAGR of 11.0% from 2023 through 2028.

The global market for prostate cancer screening and detection is expected to grow from $15.0 billion in 2023 to $19.8 billion by the end of 2028, at a CAGR of 5.8% from 2023 through 2028.

Report Scope:

This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report.

Report Includes:

• 31 data tables and 63 additional tables
• An overview of the global market for the technologies for prevention and treatment of prostate cancer
• Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
• Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region
• Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas
• Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations
• Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer
• Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer
• Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios
• Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer
• Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies
• Profiles of leading market participants

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• What's New in this Update?
• Methodology and Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Overview of Cancer
• Prostate Cancer
• Biology of Prostate Cancer
• Symptoms
• Screening
• Diagnosis
• Localized Prostate Cancer
• Metastatic Prostate Cancer
• Watchful Waiting or Active Surveillance
• Treatment
• Conclusions

Chapter 4 Market Dynamics

• Overview
• Market Drivers
• Increasing Prevalence of Prostate Cancer
• Active Surveillance and Screening
• Personalized Care
• Approvals for Metastatic Castration-Resistant Prostate Cancer
• Collaborations and Licensing Agreements
• Market Challenges
• Loss of Exclusivity and Genericization
• Shortage of Care Providers and Other Resources
• Market Opportunities

Chapter 5 Screening and Diagnosis Market by Test Type

• Market Overview
• Biomarker Tests
• PSA Tests
• Limitations of PSA Tests
• Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings
• Digital Rectal Exam
• Limitations of DREs
• Prostate Biopsy
• Grade (Gleason Score) of Prostate Cancer
• Prostatic Intraepithelial Neoplasia
• Atypical Small Acinar Proliferation
• Proliferative Inflammatory Atrophy
• Intraductal Carcinoma of the Prostate
• Limitations of Prostate Biopsies
• Imaging Technologies for Prostate Cancer
• Market for Prostate Cancer Screening/Diagnosis, by Test Type
• Biomarker Tests
• DREs
• Prostate Biopsies

Chapter 6 Pharmaceuticals Market by Drug Type

• Market Overview
• Hormone Therapy
• Androgen Deprivation Therapy
• Antiandrogen Therapies
• Hormone Therapy Uses in Prostate Cancer Treatment
• Targeted Therapy
• PARP Inhibitors
• Radioligand Therapies
• Small Molecule Targeted Agents
• Monoclonal Antibodies
• Chemotherapy
• Immunotherapy
• Market Revenue, by Drug Type
• Hormone Therapy
• Targeted Therapy
• Immunotherapy
• Chemotherapy

Chapter 7 Market for Surgery and Radiation Therapy by Treatment Type

• Market Overview
• Active Surveillance
• Radical Prostatectomy
• Robotic Prostatectomy
• Open Radical Prostatectomy
• Laparoscopic Prostatectomy
• Radical Prostatectomy Market Revenue
• Radiation Therapy
• External Beam Radiation Therapy
• Brachytherapy
• Combined Radiation Therapy
• Radiation Therapy Device Market Revenue

Chapter 8 Market Breakdown by Region

• Market Overview
• Market Revenue, by Region
• North America
• Market Revenue, by Product Type
• Europe
• Market Revenue, by Product Type
• Asia-Pacific
• Market Revenue, by Product Type
• Rest of the World (RoW)
• Market Revenue, by Product Type

Chapter 9 Emerging Technologies and Developments

• Overview
• Liquid Biopsy
• Multiparametric MRI
• Homologous Recombination Repair Gene Mutation
• Advanced Radiotherapy Techniques
• AI and Machine Learning

Chapter 10 Pipeline Analysis

• Overview
• By Company

Chapter 11 Competitive Intelligence

• Overview
• Screening and Diagnosis Market
• Market for Radiation Therapy Devices
• Pharmaceuticals Market

Chapter 12 Company Profiles

• ABBOTT
• ACCURAY INC.
• ASTELLAS PHARMA INC.
• ASTRAZENECA PLC
• BAYER AG
• DANAHER CORP.
• DENDREON PHARMACEUTICALS LLC
• ELEKTA
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• PFIZER INC.
• SANOFI
• SIEMENS HEALTHINEERS AG

Chapter 13 Appendix: Abbreviations